Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Short Interest Up 6.8% in February

Bellerophon Therapeutics, Inc. (NASDAQ:BLPHGet Rating) was the recipient of a large increase in short interest in February. As of February 28th, there was short interest totalling 164,700 shares, an increase of 6.8% from the February 13th total of 154,200 shares. Based on an average daily trading volume, of 1,970,000 shares, the short-interest ratio is currently 0.1 days.

Bellerophon Therapeutics Trading Down 5.6 %

Shares of BLPH opened at $6.44 on Thursday. The business’s 50 day moving average is $2.47 and its 200 day moving average is $1.56. The company has a market capitalization of $62.66 million, a PE ratio of -3.22 and a beta of 0.34. Bellerophon Therapeutics has a 12-month low of $0.67 and a 12-month high of $7.88.

Analysts Set New Price Targets

Separately, assumed coverage on Bellerophon Therapeutics in a research note on Monday. They set a “sell” rating on the stock.

Institutional Trading of Bellerophon Therapeutics

A hedge fund recently bought a new stake in Bellerophon Therapeutics stock. HRT Financial LP acquired a new position in Bellerophon Therapeutics, Inc. (NASDAQ:BLPHGet Rating) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 28,035 shares of the biotechnology company’s stock, valued at approximately $25,000. HRT Financial LP owned about 0.29% of Bellerophon Therapeutics at the end of the most recent reporting period. 11.36% of the stock is owned by institutional investors.

About Bellerophon Therapeutics

(Get Rating)

Bellerophon Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the development of products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Its product pipeline includes PH-ILD, PH-COPD, INOpulse and PH-Sarc. The company was founded in 2009 and is headquartered in Warren, NJ.

See Also

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with's FREE daily email newsletter.